TrialThe Lancet. Oncology2015

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

Anish Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.